Treatment Improves Outcomes in Patients With CRSwNP, Features of Obstructive Lung Disease
In the phase 3 SINUS-24 and SINUS-52 trials, dupilumab improved clinical outcomes and and health-related quality of life among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and clinical features of obstructive lung disease.
Source: ajmc.com